文献速递浆细胞疾病

HexaBody-DR5/DR5在复发/难治多发性骨髓瘤中的强效临床前活性

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.
PubMed 文献 · Blood Adv · 2021-01-01

该临床前研究评估了HexaBody-DR5/DR5(一种双表位DR5特异性IgG1抗体混合物,含E430G突变促进六聚化)在48例多发性骨髓瘤患者骨髓样本中的细胞毒性。结果显示其在复发/难治患者(包括达雷妥尤单抗难治者)中细胞毒性最强,且与硼替佐米或来那度胺联用可协同增强杀伤,提示近期治疗可能致敏MM细胞。

要点

  • HexaBody-DR5/DR5在复发/难治MM患者样本中诱导最强细胞毒性,包括达雷妥尤单抗难治者。
  • 仅末次抗MM治疗<1个月的患者中观察到增强的细胞毒性,提示药物致敏作用。
  • 硼替佐米与HexaBody-DR5/DR5在7/11例新诊断患者中协同增加细胞毒性。

核心结论

  • HexaBody-DR5/DR5在复发/难治MM中展现治疗潜力,尤其近期接受过治疗的患者。

研究设计与样本

  • 临床前研究,使用48例MM患者骨髓样本评估HexaBody-DR5/DR5的细胞毒性。

主要发现

  • HexaBody-DR5/DR5在48例MM患者骨髓样本中诱导原代MM细胞强效细胞毒性。
  • 在复发/难治MM患者(包括达雷妥尤单抗难治者)样本中细胞毒性最高。
  • 增强的细胞毒性仅见于末次抗MM治疗<1个月的患者。
  • 硼替佐米联合HexaBody-DR5/DR5在7/11例新诊断患者中协同增加细胞毒性。
  • 来那度胺通过免疫调节作用协同,达雷妥尤单抗联合呈 additive 效应。

临床怎么用

  • HexaBody-DR5/DR5可能尤其适用于近期接受过治疗的复发/难治MM患者。
  • 与硼替佐米或来那度胺联用可能增强疗效,达雷妥尤单抗联用呈 additive 效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Apoptosis induction by death receptor (DR)-specific agonistic antibodies is a potentially effective antitumor therapy. Nonetheless, to date, all conventional DR-targeting antibodies that induce apoptosis via FcγR-dependent DR clustering failed to show clinical efficacy. HexaBody-DR5/DR5 (GEN1029) has been developed to overcome full FcγR dependence. HexaBody-DR5/DR5 is a mixture of 2 noncompeting DR5-specific immunoglobulin G1 (IgG1) antibodies, each with an E430G mutation in the Fc domain. This mutation enhances Fc-Fc interactions, resulting in antibody hexamerization, followed by FcγR-independent clustering of DR5 molecules. This unique combination of dual epitope targeting and increased IgG hexamerization resulted in potent preclinical antitumor activity in various solid cancers. In this study, we explored the preclinical activity of HexaBody-DR5/DR5 in multiple myeloma (MM), because MM cells are known to express DR5. In bone marrow samples from 48 MM patients, HexaBody-DR5/DR5 induced potent cytotoxicity of primary MM cells. Importantly, HexaBody-DR5/DR5 mediated the highest cytotoxic activity in samples from relapsed/refractory MM patients, including those who are refractory to daratumumab. This improved cytotoxic activity was observed only in patients who received their last anti-MM treatment <1 month ago, suggesting that anti-MM drugs sensitized MM cells to HexaBody-DR5/DR5. Supporting this, bortezomib combined with HexaBody-DR5/DR5 synergistically increased cytotoxicity in MM cells in 7 of 11 newly diagnosed patients. Lenalidomide also synergized with HexaBody-DR5/DR5, but only via its immunomodulatory effects, presumably by enhancing the antibody-dependent cellular cytotoxicity activity of HexaBody-DR5/DR5. Daratumumab showed additive effects when combined with HexaBody-DR5/DR5. In conclusion, the results of this preclinical study indicate a therapeutic potential for HexaBody-DR5/DR5, especially in recently treated relapsed/refractory MM patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van der Horst HJ, Gelderloos AT, Chamuleau MED, et al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021. PMID: 33885752. doi:10.1182/bloodadvances.2020003731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。